Paratek Pharmaceuticals (FRA:N4CN) Debt-to-Equity : -1.29 (As of Jun. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Paratek Pharmaceuticals Debt-to-Equity?

Paratek Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €151.4 Mil. Paratek Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €88.3 Mil. Paratek Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2023 was €-185.9 Mil. Paratek Pharmaceuticals's debt to equity for the quarter that ended in Jun. 2023 was -1.29.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Paratek Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

FRA:N4CN' s Debt-to-Equity Range Over the Past 10 Years
Min: -19.21 Med: -1.33 Max: 14.48
Current: -1.29

During the past 13 years, the highest Debt-to-Equity Ratio of Paratek Pharmaceuticals was 14.48. The lowest was -19.21. And the median was -1.33.

FRA:N4CN's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs FRA:N4CN: -1.29

Paratek Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Paratek Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals Debt-to-Equity Chart

Paratek Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

4.81

-6.63

-2.46

-2.00

-1.51

Paratek Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Debt-to-Equity	Get a 7-Day Free Trial															-1.73	-1.56	-1.51	-1.37	-1.29

Competitive Comparison of Paratek Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Paratek Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paratek Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Paratek Pharmaceuticals's Debt-to-Equity falls into.

Paratek Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Paratek Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	243.943)	/	-161.464
	=	-1.51

Paratek Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(151.411	+	88.344)	/	-185.86
	=	-1.29

Paratek Pharmaceuticals (FRA:N4CN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Paratek Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Paratek Pharmaceuticals (FRA:N4CN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (FRA:N4CN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 Park Plaza, 4th Floor, Boston, MA, USA, 02116

Website

https://www.paratekpharma.com

Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Paratek Pharmaceuticals (FRA:N4CN) Headlines

No Headlines